Abstract
Background: Malignant pleural mesothelioma (MPM) is a highly aggressive cancer with less than a 10% 5-year survival rate. Arginine deprivation using pegylated arginine deiminase (ADI-PEG20) is a promising anti-metabolite strategy for MPM cells deficient in the arginine biosynthetic enzyme ASS1. However, resistance to ADI-PEG20 in MPM is a significant problem and is characterized in part by reprogramming of the urea and polyamine metabolism pathway. We sought to identify a targeted metabolism-based therapy to overcome the emerging resistance and increase the efficiency of ADI-PEG20 treatment for MPM patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
